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doi:10.1016/j.ejvs.2008.06.036Abstract Objectives: To investigate the immediate effects of Nordic pole walking (NPW) on
walking distance and cardiopulmonary workload in patients with intermittent claudication.
Methods: Using a standardised treadmill test (3.2 km h1 at 4% gradient), walking distance,
cardiopulmonary responses, leg pain and perceived exertion during NPW were compared to
responses evoked by normal walking in 20 patients with intermittent claudication. The
distance to onset of claudication pain (claudication distance: CD) and to maximum walking
distance (MWD), heart rate (HR), expired gas parameters, leg pain (Borg’s CR-10 Scale) and
perceived exertion (Borg’s Rating of Perceived Exertion: RPE Scale) were compared.
Results: CD increased significantly from a median (range) distance of 77 m (28e503) to 130 m
(41e1080) and MWD increased significantly from 206 m (81e1078) to 285 m (107e1080) when
patients used the Nordic poles (PZ 0.000). The level of leg pain at MWD was also significantly
reduced during NPW (PZ 0.002). Perceived exertion at MWD did not increase despite an increase
in cardiopulmonary work, as indicated by an increase in oxygen consumption (16.5%; PZ 0.000).
Conclusion: These results show that NPW immediately enables patients with intermittent
claudication to walk further with less pain, despite a higher workload. NPW might also be
a useful exercise strategy for improving the cardiovascular fitness of patients with intermittent
claudication.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Narrowing of the arteries in the legs caused by athero-
sclerotic peripheral arterial disease (PAD) can limit lower-siotherapy and Circulation
hill, Sheffield S10 2QN, UK.
ernet.com (C. Oakley).
ty for Vascular Surgery. Publishelimb blood flow during walking. This leads to a cramp-like
pain (intermittent claudication) in the calf muscles on
walking. Intermittent claudication affects up to 20% of the
elderly population and 50% of claudicants die within
10 years.1 Risk factor modification reduces vascular events
such as myocardial infarction and stroke by one-third, but
there is little evidence that it improves walking distance.2
Surgical or endovascular revascularisation is not appro-
priate for many of these patients because of the diffuse
nature of their arterial disease.3d by Elsevier Ltd. All rights reserved.
Table 1 Demographics of the patient cohort
Variable
Median age (range) 70 (57e79)
Body weight (kg) 86.7 3.3
Height (m) 1.76 0.01
Body mass
index (kg m2)
27.8 1.0
Resting ABPI 0.61 0.04
Smoking status (%)
Current 30
Previous 65
Never smoked 5
Anti hypertensive
medication (%)
45
Beta-blockers (%) 45
Previous heart
attack (%)
40
Controlled angina (%) 70
Previous stroke (%) 10
Diabetes (%) 40
Statins (%) 100
Anti-platelet agents (%) 100
ABPI data are presented for the most symptomatic limb. Unless
otherwise stated, values are means SE.
690 C. Oakley et al.Exercise therapy is a relatively inexpensive, low risk
treatment, compared to interventional procedures. Regular
supervised exercise can improve walking distance.4 The
greatest benefits seem to be when patients exercise three
times a week, for 30 min and walk to maximal pain levels.5 A
recent meta-analysis has shown that supervised exercise
therapy increases walking distance more than unsupervised
exercise, but the cost-effectiveness has been questioned.6
This is because supervised exercise programmes are
relatively expensive to run and long-term compliance can be
a problem.
Despite an extensive body of evidence supporting the
positive effects of lower-limb exercise rehabilitation,
physical activity levels are lower in patients with symp-
tomatic peripheral arterial disease than in age-matched
controls.7 Alternative exercise modalities that can reduce
the level of ischaemic pain resulting from lower-limb
exertion might help some patients to overcome the barriers
to conventional forms of exercise rehabilitation (i.e.,
walking) and increase their enthusiasm for maintaining
a physically active lifestyle. We have recently shown that
upper-limb aerobic exercise training is well tolerated in
patients with intermittent claudication8 and can evoke
symptomatic improvements in this patient group.9,10
Although the mechanisms remain unclear, it is probably due
to improved cardiovascular fitness.11
Nordic pole walking (NPW) is a form of exercise that
involves a significant contribution from the upper-limbs and
shoulders (used predominately during forward propulsion)
and could lead to an improved exercise tolerance in this
patient group. NPW has become an accepted form of
exercise training for athletes and is a popular recreational
sport in Scandinavia. In athletes NPW results in a significant
increase in oxygen use (23%) and caloric expenditure (22%)
compared to regular walking, without an increase in
perceived exertion.12 NPW has also been shown to improve
cardiovascular fitness in patients with intermittent
claudication.13
Although previous research has studied the physiological
responses to NPW in healthy individuals,14e16 and patients
with coronary artery disease,17 the immediate effects of
NPW in patients with intermittent claudication have not
been studied. The primary aim of this study was to inves-
tigate whether NPW improves the walking distance in
patients with intermittent claudication and secondly, to
compare the cardiopulmonary responses, level of leg pain
and perceived exertion evoked by NPW with those evoked
by normal walking in this patient group.
Materials and Methods
Patients
A total of 21 male patients (median age 70 yrs, range 57e79
yrs) with stable intermittent claudication (defined as
having stable symptoms and no intervention for over
6 months) were recruited from the Sheffield Vascular
Institute at the Northern General Hospital, Sheffield, UK.
Patients were recruited consecutively from the vascular
clinic, without any selection bias. They had symptoms of
variable severity (Table 1). The clinical diagnosis of PADwas established on the basis of the patient’s history and
physical examination, and was confirmed by Doppler
assessment of resting ankle-brachial pressure index (ABPI)
of <0.9. Patients were excluded if they had exercise
limiting angina; shortness of breath on exercise; severe
arthritis or any other condition which prevented them from
undertaking exercise. All the patients in this study had
infra-inguinal disease which was not amenable to straight-
forward open or endovascular intervention. One patient
was excluded because, although on the flat he could walk
well with poles, he was unable to walk at the required
speed on the treadmill. Ethical approval was obtained from
the North Sheffield Local Research Ethics Committee and
all patients provided informed consent before entering the
study. Demographic data for the patient cohort are
provided in Table 1.
Treadmill and NPW familiarisation
All patients attended the Exercise Laboratory for a famil-
iarisation session, which lasted about an hour. Patients
received comprehensive instructions on the NPW technique
and were allowed ample practice time until members of the
research team and patients themselves were confident that
they had mastered the technique. During this session,
patients initially walked on a flat treadmill at a slow speed,
but as they gained confidence a target speed of 3.2 km h1
was reached and the incline was raised to 4%. After this
they were instructed to walk on the treadmill (3.2 km h1
at 4% gradient) both with and without poles to maximum
walking distance (maximum exercise tolerance). A 15 min
rest recovery period was allowed between the two practice
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with the expired gas analysis system, heart rate monitors,
Borg’s perceived exertion and pain scales18 and the use of
the safety harness during treadmill walking.
Treadmill walking assessments
Patients attended the laboratory where they performed
two treadmill walking tests at the same constant walking
speed and gradient (3.2 km h1 and 4%, respectively) with
a suitable rest period between the tests to ensure that they
were adequately rested. One of the treadmill tests involved
normal walking, without Nordic poles, and the other test
involved walking with Nordic poles. A treadmill with an
extra wide belt width was used (Saturn, HP Cosmos, Ger-
many) providing ample room to enable correct pole walking
technique. The speed of the treadmill protocol complies
with internationally accepted recommendations for the
clinical assessment of patients with PAD.19 A gradient of 4%
was chosen for the treadmill protocol, as pilot work with
claudicants showed that most patients could walk
a distance >80 m before experiencing intolerable claudi-
cation pain at this setting. This study was a crossover
design, with the order of the two tests (walking with and
without Nordic poles) being randomised for each patient.
The maximum duration (distance) of the treadmill test
protocol was set at 20 min (1080 m). Randomisation was
performed just before the first walking test using a modified
fishbowl technique.
Outcome measures
The distance walked before the onset of claudication pain
(claudication distance, CD) and the maximum walking
distance (MWD) which was achieved before the test was
terminated due to intolerable claudication pain were
recorded. Patients’ oxygen consumption, ( _VO2) and other
indices of cardiopulmonary work, including the minute
volume of expired air ( _VE) and respiratory exchange ratio
(RER: _VCO2= _VO2) were measured breath by breath
throughout the test, using an online gas analysis system
(Ultima, Medical Graphics Corporation, USA). Heart rate
(HR) was also continuously monitored using a polar HR
monitor (Beat, Polar Electro-OY, Finland) and peak oxygen
pulse at MWD was derived from oxygen consumption
divided by HR (ml beat1). Ratings of perceived exertion
(Borg RPE Scale18) at MWD and leg pain (Borg Category
Ratio-10 (CR-10) Scale18) at CD and MWD were recorded.
Blood pressure (BP) and ABPI were measured before and
immediately after the test, and BP at 5 min intervals until it
had returned to pre-test levels. Immediately after each
treadmill assessment, patients were asked to state their
reason for terminating the test.
Data analysis
Descriptive statistics were obtained. All dependent vari-
ables were first tested for normal distribution using the
KolmogoroveSmirnov goodness of fit test. The walking data
(CD and MWD) were positively skewed and violated the
assumption of normality, which is a common finding inclaudication studies. As the CD and MWD data could not be
normalised using data transformation techniques, the
Wilcoxon signed ranks test for paired data was used to test
for differences between the walking distances. The signif-
icance level was set at P< 0.05. Differences in the other
dependent variables between the two conditions were
analysed using the paired t-test. As multiple comparisons
were being made, the alpha level was set to P< 0.005 using
the Bonferroni correction to reduce the likelihood of type I
errors. Data were analysed using the SPSS (version 13.0)
statistical package (SPSS UK Ltd., Woking, UK.).
Results
Each patient performed the two walking tests (with and
without Nordic poles) in random order. Two patients were
able to walk for 20 min with Nordic poles. For these
patients the test was terminated, since this was the
maximum time allocated for the test. Their CD and MWD
were, therefore, taken to equal the maximum distance of
1080 m. It was not possible to compare the cardiopulmo-
nary data at CD or MWD in these two patients. Hence the
gas analysis comparisons are based on data from 18 patients
only. These two patients were stopped by claudication pain
when walking without poles.
There was no significant difference in results whichever
test was performed first (8 patients performed the NPW
test first, 12 patients performed the ‘no poles’ test first).
Patients were allowed adequate recovery time between
tests to ensure that they were rested before the second
test.
Walking distances
CD increased significantly from a median (range) distance
of 77 m (28e503) without poles to 130 m (41e1080) with
poles (PZ 0.000; Fig. 1A), representing a 69% increase.
MWD increased significantly from 206 m (81e1078) without
poles to 285 m (107e1080) with poles (PZ 0.000; Fig. 1B),
representing a 38% increase. A large range in patients’
individual percentage improvement was observed. CD
increased by 15e273% (median 64%) and MWD increased by
2.4e389% (median 64%).
ABPI
The decrease in ABPI (mean SE) for the most symptomatic
leg was less after NPW (0.15 0.03), than after walking
without the poles (0.20 0.03), but the difference was not
significant (PZ 0.10).
Pain (Borg’s CR-10 Scale)
As expected, patients’ perception of the onset of claudi-
cation pain was similar between the two walking tests.
At MWD patients experienced less pain when using the
Nordic poles (4.3 0.5 versus 5.6 0.5 on the Borg CR-10
Scale; PZ 0.002), corresponding to a change in pain
perception from ‘‘strong (heavy)’’ to ‘‘somewhat strong’’.
The reduction in leg pain with NPW, expressed as mean
difference (95% confidence interval), was 1.4 (0.6e2.2)
Figure 1 Effect of normal walking and NPW on pain-free (claudication) distance in individuals (upper) and the group as a whole
(lower). *P< 0.000, vs normal walking, Wilcoxon signed ranks test (A). Effect of normal walking and NPW on maximum walking
distance (MWD) in individuals (upper) and the group as a whole (lower). *P< 0.000, vs normal walking, Wilcoxon signed ranks test
(B). Data are expressed as medians and the 25th and 75th quartiles.
692 C. Oakley et al.Borg CR-10 units (Fig. 2). Importantly, eight of the 20
patients terminated the NPW test for reasons other than
claudication pain (e.g., breathlessness, exhaustion, tired-
ness). All the ‘no pole’ tests were stopped because of
claudication pain.
Cardiopulmonary variables
The results for all the cardiopulmonary variables and
perceived exertion data are reported in Table 2. _VO2 was
increased by 18% at CD (PZ 0.002) and by 16.5% at MWD
(PZ 0.000) with NPW. This increased level of oxygen
consumption at CD and MWD were accompanied by
a significant increase in _VE at CD and MWD (PZ 0.001) and
there was a trend for an increase in RER at MWD (PZ 0.02).
HR was significantly elevated by 7% (PZ 0.000) at CD and
by 9% at MWD (PZ 0.46) when patients walked with Nordic
poles. The peak oxygen pulse (ml of oxygen consumption
per heart beat) was also significantly increased at MWD
during NPW (PZ 0.007). Despite the increase in cardio-
pulmonary work at MWD, perceived exertion at maximum
exercise tolerance (MWD) was not different between the
two walking tests (PZ 0.65).Discussion
This is the first study to compare the immediate benefits of
NPW in patients with intermittent claudication. The
results demonstrate that NPW causes an immediate and
significant increase in the distances patients can walk to
CD and MWD at a walking speed of 3.2 km h1, and that
NPW evokes a significantly higher level of cardiopulmonary
work, as evidenced by a higher HR, _VO2 and _VE at CD and
increased levels of _VO2, _VE, RER and oxygen pulse at MWD.
Despite increased work during NPW, perceived exertion at
MWD was similar and patients experienced less leg pain
when walking with Nordic poles. This suggests that NPW
could be a useful method of improving cardiovascular
fitness in claudicants who are usually unable to walk fast
enough or for long enough for this response to occur. It
might also be a more acceptable form of exercise for these
patients because of the lower level of leg pain
experienced.
As NPW enables patients with intermittent claudication
to immediately walk further, it could have a huge impact on
their lifestyle. Patients were able to walk between
15e273% further before experiencing the onset of
Figure 2 Reduction in perception of leg pain at claudication
(CD) and maximum walking distance (MWD) with NPW,
compared to normal walking. Data are expressed as the mean
difference (95% confidence interval) in Borg CR-10 units.
*PZ 0.002, paired t-test.
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stop due to intolerable leg pain or other factors, such as
breathlessness and feelings of tiredness etc. The large
range in walking distances with Nordic poles might be
explained by differences in NPW technique, cardiovascular
fitness and medication (e.g., beta-blockers).
The median increases in CD (69%) and MWD (38%) were
lower than those typically observed following programmes
of exercise training in patients with intermittent claudica-
tion,4 but these improvements were immediate and
represent clinically important changes for most of the
patients. The eight patients who terminated the NPW test
due to tiredness and exhaustion were excited by their first
comparatively painless workout for a long time. The two
patients who were able to walk for the maximum 20 min
duration with poles immediately bought their own Nordic
poles.
The decreased level of leg pain during NPW is attribut-
able to a reduction in lower-limb loading stress. Willson
et al. (2001) showed that the use of walking poles enables
individuals to walk at faster speeds with lower groundTable 2 Indices of cardiopulmonary stress (work) and perceive
NPW Normal
HR at CD (beats min1) 107 5 100
HR at MWD (beats min1) 115 4 112
_VO2 at CD (l min
1) 1.12 0.08 0.95
_VO2 at MWD (l min
1) 1.20 0.05 1.03
_VE at CD (l min1) 35.17 2.61 28.63
_VE at MWD (l min1) 45.23 2.59 38.20
RER at CD (l min1) 0.88 0.01 0.84
RER at MWD (l min1) 0.98 0.02 0.92
RPE at MWD 14.6 0.6 14.4
Oxygen pulse
at MWD (ml beat1)
10.83 0.69 9.63
Unless otherwise stated, data in Table 2 are presented as means SE
and normal walking conditions of the study.reaction and vertical knee joint forces and with a reduced
knee extensor angular impulse and support moment.20 It
has been suggested by Collins et al. (2003) that the longer
stride may allow the calf muscles longer recovery time and,
therefore, use the limited blood supply more efficiently.21
That effect, coupled with change in weight distribution
through the legs may explain why the patients can walk
further immediately.
The involvement of the trunk, arm and shoulder muscles
during NPW accounts for the increase in cardiopulmonary
work at a given walking speed.15 _VO2 was increased by
16e18% and _VE was increased by 18e23% between CD and
MWD with NPW. These increases are similar to previous
studies in healthy men and women, which have reported
elevations in HR in the range of 9e16% and increases in
oxygen consumption in the range of 8e23% during NPW in
comparison to normal walking.12e16 The relatively small
increases in HR (7% at CD and 9% at MWD) are probably
explained by the high percentage of patients (45%) on beta-
blockers, which can limit HR. The increase in oxygen pulse
at MWD suggests that stroke volume increased significantly
despite beta-blockade.
Perceived exertion with or without Nordic poles at MWD
was similar, suggesting that leg pain influences this variable
in claudicants. The increase in cardiopulmonary work for
a given level of perceived exertion suggests that the use of
Nordic poles could be a useful strategy for increasing the
cardiovascular fitness in this patient group. This could have
important clinical implications for patients who cannot
normally walk far enough or fast enough to provide a suffi-
cient cardiopulmonary exercise stimulus.17 In addition, the
lower level of leg pain encountered during walking together
with the increased distance could make this form of exer-
cise rehabilitation more appealing to patients, and
encourage better compliance to a physically active life-
style. In this respect, previous research has reported both
qualitative and quantitative improvements in walking
performance following a 24-week programme of NPW
training in patients with intermittent claudication.13 A 51%
improvement in treadmill walking time, reduced percep-
tion of claudication pain and improvements in perceived
distance and walking speed scores on the Walking Impair-
ment Questionnaire22 were reported by Langbein et al.d exertion during NPW and normal walking
walking Mean difference
(95% confidence interval)
P-value
5 7 (4e9) 0.000
6 3 (5e11) 0.456
0.06 0.17 (0.07e0.26) 0.002
0.06 0.18 (0.09e0.26) 0.000
1.84 6.55 (2.90e10.19) 0.001
2.44 7.03 (3.11e10.96) 0.001
0.02 0.03 (0e0.07) 0.077
0.03 0.05 (0.01e0.10) 0.016
0.03 0.3 (0.9e1.4) 0.653
0.73 1.20 (0.38e2.02) 0.007
. P-values are shown for paired t-test comparisons between NPW
694 C. Oakley et al.(2002)13 after 24 weeks of polestriding training. In addition
‘an enhanced mood’ in pole walkers, compared to either of
the other two groups (control and exercise classes) has
been reported by Stoughton (1992).23 This feel good factor
was very evident in our study.
Conclusion
Our results demonstrate that NPW immediately enables
patients with intermittent claudication to walk further with
less leg pain, despite higher cardiopulmonary work at MWD.
NPW could, therefore, be a useful exercise strategy for
increasing thecardiovascular fitness of thesepatients. Further
research is needed to explore the training effect, cost effec-
tiveness and long-term benefits of NPW in these patients.
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